Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial program

被引：0
|
作者：
Eichenfield, Lawrence F. [1 ,2 ]
Flohr, Carsten [3 ]
Bangert, Christine [4 ]
Irvine, Alan D. [5 ]
Weidinger, Stephan [6 ]
Nesnas, John [7 ]
Koppensteiner, Herwig [8 ]
Zhang, Fan [9 ]
Rojo, Ricardo [9 ]
Chan, Gary [9 ]
机构：
[1] Univ Calif San Diego, San Diego, CA USA
[2] Radys Childrens Hosp San Diego, San Diego, CA USA
[3] Kings Coll London, Guys & St ThomasNHS Fdn Trust, St Johns Inst Dermatol, Unit Populat Based Dermatol Res, London, England
[4] Med Univ Vienna, Vienna, Austria
[5] Univ Dublin, St James Hosp, Trinity Coll Dublin, Dublin, Ireland
[6] Univ Hosp Schleswig Holstein, Kiel, Germany
[7] Pfizer Ltd, Tadworth, Surrey, England
[8] Pfizer Inc, Vienna, Austria
[9] Pfizer Inc, Groton, CT USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
abrocitinib; adolescents; moderate-to-severe atopic dermatitis;
D O I：
10.1093/bjd/ljad162.046
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
426
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of abrocitinib in adolescents with moderate-to-severe atopic dermatitis from the JADE clinical trial programme
    Eichenfield, L. F.
    Flohr, C.
    Bangert, C.
    Irvine, A. D.
    Weidinger, S.
    Nesnas, J.
    Koppensteiner, H.
    Zhang, F.
    Rojo, R.
    Chan, G.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E142 - E143
  • [2] Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis The JADE TEEN Randomized Clinical Trial
    Eichenfield, Lawrence F.
    Flohr, Carsten
    Sidbury, Robert
    Siegfried, Elaine
    Szalai, Zsuzsanna
    Galus, Ryszard
    Yao, Zhirong
    Takahashi, Hidetoshi
    Barbarot, Sebastien
    Feeney, Claire
    Zhang, Fan
    DiBonaventura, Marco
    Rojo, Ricardo
    Valdez, Hernan
    Chan, Gary
    [J]. JAMA DERMATOLOGY, 2021, 157 (10) : 1165 - 1173
  • [3] Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Gooderham, Melinda
    Chan, Gary
    Feeney, Claire
    Biswas, Pinaki
    Valdez, Hernan
    DiBonaventura, Marco
    Nduaka, Chudy
    Rojo, Ricardo
    [J]. JAMA DERMATOLOGY, 2020, 156 (08) : 863 - 873
  • [4] EFFICACY AND SAFETY OF ABROCITINIB MONOTHERAPY IN ADULTS AND ADOLESCENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A POST HOC ANALYSIS OF JADE REGIMEN
    Flohr, Carsten
    Cork, Michael J.
    Eichenfield, Lawrence F.
    Feeney, Claire
    Koppersteiner, Herwig
    Lazariciu, Irina
    Nesnas, John
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 31 - 31
  • [5] Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    Bangert, Christine
    Irvine, Alan D.
    Weidinger, Stephan
    Johnson, Susan
    Lazariciu, Irina
    Koppensteiner, Herwig
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 77
  • [6] Integrated analysis of abrocitinib for the treatment of adolescents with moderate-to-severe atopic dermatitis from the phase 3 clinical trial program
    Paller, Amy
    Eichenfield, Lawrence F.
    Cork, Michael J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB72 - AB72
  • [7] Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
    Li, Ling
    Yu, Jiajun
    Chen, Baoqing
    Guo, Ying
    Yang, Yufeng
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [8] Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial (vol 157, pg 1165, 2021)
    Zouboulis, C. C.
    Tzellos, T.
    Kyrgidis, A.
    [J]. JAMA DERMATOLOGY, 2021, 157 (10) : 1246 - 1246
  • [9] Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
    Shi, Vivian Y.
    Bhutani, Tina
    Fonacier, Luz
    Deleuran, Mette
    Shumack, Stephen
    Valdez, Hernan
    Zhang, Fan
    Chan, Gary L.
    Cameron, Michael C.
    Yin, Natalie C.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (02) : 351 - 358
  • [10] Efficacy and safety of abrocitinib in combination with topical therapy in adolescents from China with moderate-to-severe atopic dermatitis: A post hoc analysis of the JADE TEEN phase 3 trial
    Yao, Zhirong
    Xu, Aie
    He, Li
    Ding, Yangfeng
    Hu, Guohong
    Vyas, Shefali
    Wang, Bo
    Luo, Xin
    Li, Shiqi
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II23 - II24
12345